Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Hallengärd D[au]:

Search results

Items: 27

1.

HIVIS-DNA or HIVISopt-DNA priming followed by CMDR vaccinia-based boosts induce both humoral and cellular murine immune responses to HIV.

Hinkula J, Petkov S, Ljungberg K, Hallengärd D, Bråve A, Isaguliants M, Falkeborn T, Sharma S, Liakina V, Robb M, Eller M, Moss B, Biberfeld G, Sandström E, Nilsson C, Markland K, Blomberg P, Wahren B.

Heliyon. 2017 Jun 29;3(6):e00339. doi: 10.1016/j.heliyon.2017.e00339. eCollection 2017 Jun.

2.

Attenuated and vectored vaccines protect nonhuman primates against Chikungunya virus.

Roques P, Ljungberg K, Kümmerer BM, Gosse L, Dereuddre-Bosquet N, Tchitchek N, Hallengärd D, García-Arriaza J, Meinke A, Esteban M, Merits A, Le Grand R, Liljeström P.

JCI Insight. 2017 Mar 23;2(6):e83527. doi: 10.1172/jci.insight.83527.

3.

Therapeutics and vaccines against chikungunya virus.

Ahola T, Couderc T, Ng LF, Hallengärd D, Powers A, Lecuit M, Esteban M, Merits A, Roques P, Liljeström P.

Vector Borne Zoonotic Dis. 2015 Apr;15(4):250-7. doi: 10.1089/vbz.2014.1681. Review. Erratum in: Vector Borne Zoonotic Dis. 2015 Nov;15(11):712. Courderc, Therese [Corrected to Couderc, Therese].

PMID:
25897811
4.

Prime-boost immunization strategies against Chikungunya virus.

Hallengärd D, Lum FM, Kümmerer BM, Lulla A, Lulla V, García-Arriaza J, Fazakerley JK, Roques P, Le Grand R, Merits A, Ng LF, Esteban M, Liljeström P.

J Virol. 2014 Nov;88(22):13333-43. doi: 10.1128/JVI.01926-14. Epub 2014 Sep 10.

5.

Kinetic and phenotypic analysis of CD8+ T cell responses after priming with alphavirus replicons and homologous or heterologous booster immunizations.

Knudsen ML, Ljungberg K, Kakoulidou M, Kostic L, Hallengärd D, García-Arriaza J, Merits A, Esteban M, Liljeström P.

J Virol. 2014 Nov;88(21):12438-51. doi: 10.1128/JVI.02223-14. Epub 2014 Aug 13.

6.

Oral delivery of plant-derived HIV-1 p24 antigen in low doses shows a superior priming effect in mice compared to high doses.

Lindh I, Bråve A, Hallengärd D, Hadad R, Kalbina I, Strid Å, Andersson S.

Vaccine. 2014 Apr 25;32(20):2288-93. doi: 10.1016/j.vaccine.2014.02.073. Epub 2014 Mar 12.

PMID:
24631072
7.

A novel poxvirus-based vaccine, MVA-CHIKV, is highly immunogenic and protects mice against chikungunya infection.

García-Arriaza J, Cepeda V, Hallengärd D, Sorzano CÓ, Kümmerer BM, Liljeström P, Esteban M.

J Virol. 2014 Mar;88(6):3527-47. doi: 10.1128/JVI.03418-13. Epub 2014 Jan 8.

8.

Micro-minicircle Gene Therapy: Implications of Size on Fermentation, Complexation, Shearing Resistance, and Expression.

Stenler S, Wiklander OP, Badal-Tejedor M, Turunen J, Nordin JZ, Hallengärd D, Wahren B, Andaloussi SE, Rutland MW, Smith CI, Lundin KE, Blomberg P.

Mol Ther Nucleic Acids. 2014 Jan 7;2:e140. doi: 10.1038/mtna.2013.67.

9.

Novel attenuated Chikungunya vaccine candidates elicit protective immunity in C57BL/6 mice.

Hallengärd D, Kakoulidou M, Lulla A, Kümmerer BM, Johansson DX, Mutso M, Lulla V, Fazakerley JK, Roques P, Le Grand R, Merits A, Liljeström P.

J Virol. 2014 Mar;88(5):2858-66. doi: 10.1128/JVI.03453-13. Epub 2013 Dec 26.

10.

Broad and potent cellular and humoral immune responses after a second late HIV-modified vaccinia virus ankara vaccination in HIV-DNA-primed and HIV-modified vaccinia virus Ankara-boosted Swedish vaccinees.

Nilsson C, Godoy-Ramirez K, Hejdeman B, Bråve A, Gudmundsdotter L, Hallengärd D, Currier JR, Wieczorek L, Hasselrot K, Earl PL, Polonis VR, Marovich MA, Robb ML, Sandström E, Wahren B, Biberfeld G.

AIDS Res Hum Retroviruses. 2014 Mar;30(3):299-311. doi: 10.1089/AID.2013.0149. Epub 2013 Nov 15.

11.

Consensus HIV-1 FSU-A integrase gene variants electroporated into mice induce polyfunctional antigen-specific CD4+ and CD8+ T cells.

Krotova O, Starodubova E, Petkov S, Kostic L, Agapkina J, Hallengärd D, Viklund A, Latyshev O, Gelius E, Dillenbeck T, Karpov V, Gottikh M, Belyakov IM, Lukashov V, Isaguliants MG.

PLoS One. 2013 May 8;8(5):e62720. doi: 10.1371/journal.pone.0062720. Print 2013.

12.

A truncated plasmid-encoded HIV-1 reverse transcriptase displays strong immunogenicity.

Hallengärd D, Wahren B, Bråve A.

Viral Immunol. 2013 Apr;26(2):163-6. doi: 10.1089/vim.2012.0083.

PMID:
23573980
13.

Cellular immunogenicity of novel gene immunogens in mice monitored by in vivo imaging.

Starodubova E, Krotova O, Hallengärd D, Kuzmenko Y, Engström G, Legzdina D, Latyshev O, Eliseeva O, Karin Maltais A, Tunitskaya V, Karpov V, Bråve A, Isaguliants M.

Mol Imaging. 2012 Nov-Dec;11(6):471-86.

PMID:
23084248
14.

Immunization with multiple vaccine modalities induce strong HIV-specific cellular and humoral immune responses.

Hallengärd D, Applequist SE, Nyström S, Maltais AK, Marovich M, Moss B, Earl P, Nihlmark K, Wahren B, Bråve A.

Viral Immunol. 2012 Oct;25(5):423-32. doi: 10.1089/vim.2012.0046.

PMID:
23035853
15.

A combination of intradermal jet-injection and electroporation overcomes in vivo dose restriction of DNA vaccines.

Hallengärd D, Bråve A, Isaguliants M, Blomberg P, Enger J, Stout R, King A, Wahren B.

Genet Vaccines Ther. 2012 Aug 8;10(1):5. doi: 10.1186/1479-0556-10-5.

16.

Rational design of HIV vaccines and microbicides: report of the EUROPRISE annual conference 2011.

Ruffin N, Borggren M, Euler Z, Fiorino F, Grupping K, Hallengärd D, Javed A, Mendonca K, Pollard C, Reinhart D, Saba E, Sheik-Khalil E, Sköld A, Ziglio S, Scarlatti G, Gotch F, Wahren B, Shattock RJ.

J Transl Med. 2012 Jul 11;10:144. doi: 10.1186/1479-5876-10-144.

17.

Comparison of plasmid vaccine immunization schedules using intradermal in vivo electroporation.

Hallengärd D, Haller BK, Maltais AK, Gelius E, Nihlmark K, Wahren B, Bråve A.

Clin Vaccine Immunol. 2011 Sep;18(9):1577-81. doi: 10.1128/CVI.05045-11. Epub 2011 Jul 13.

18.

Rational design of HIV vaccines and microbicides: report of the EUROPRISE network annual conference 2010.

Brinckmann S, da Costa K, van Gils MJ, Hallengärd D, Klein K, Madeira L, Mainetti L, Palma P, Raue K, Reinhart D, Reudelsterz M, Ruffin N, Seifried J, Schäfer K, Sheik-Khalil E, Sköld A, Uchtenhagen H, Vabret N, Ziglio S, Scarlatti G, Shattock R, Wahren B, Gotch F.

J Transl Med. 2011 Apr 12;9:40. doi: 10.1186/1479-5876-9-40.

19.

Increased expression and immunogenicity of HIV-1 protease following inactivation of the enzymatic activity.

Hallengärd D, Haller BK, Petersson S, Boberg A, Maltais AK, Isaguliants M, Wahren B, Bråve A.

Vaccine. 2011 Jan 17;29(4):839-48. doi: 10.1016/j.vaccine.2010.10.083. Epub 2010 Nov 23.

PMID:
21109032
20.

Biodistribution, persistence and lack of integration of a multigene HIV vaccine delivered by needle-free intradermal injection and electroporation.

Bråve A, Gudmundsdotter L, Sandström E, Haller BK, Hallengärd D, Maltais AK, King AD, Stout RR, Blomberg P, Höglund U, Hejdeman B, Biberfeld G, Wahren B.

Vaccine. 2010 Nov 29;28(51):8203-9. doi: 10.1016/j.vaccine.2010.08.108. Epub 2010 Oct 15.

PMID:
20951666
21.

Rational design of HIV vaccine and microbicides: report of the EUROPRISE annual conference.

Wahren B, Biswas P, Borggren M, Coleman A, Da Costa K, De Haes W, Dieltjens T, Dispinseri S, Grupping K, Hallengärd D, Hornig J, Klein K, Mainetti L, Palma P, Reudelsterz M, Seifried J, Selhorst P, Sköld A, Uchtenhagen H, van Gils MJ, Weber C, Shattock R, Scarlatti G.

J Transl Med. 2010 Jul 26;8:72. doi: 10.1186/1479-5876-8-72. Erratum in: J Transl Med. 2010;8(1):82. Uchtenhagen, Hannes [added].

22.

Therapeutic efficacy of a DNA vaccine targeting the endothelial tip cell antigen delta-like ligand 4 in mammary carcinoma.

Haller BK, Bråve A, Wallgard E, Roswall P, Sunkari VG, Mattson U, Hallengärd D, Catrina SB, Hellström M, Pietras K.

Oncogene. 2010 Jul 29;29(30):4276-86. doi: 10.1038/onc.2010.176. Epub 2010 May 24.

PMID:
20498640
23.

Induction of HIV-1-specific cellular and humoral immune responses following immunization with HIV-DNA adjuvanted with activated apoptotic lymphocytes.

Brave A, Johansson U, Hallengärd D, Heidari S, Gullberg H, Wahren B, Hinkula J, Spetz AL.

Vaccine. 2010 Feb 25;28(9):2080-7. doi: 10.1016/j.vaccine.2009.12.040. Epub 2009 Dec 29.

PMID:
20044053
24.

Late administration of plasmid DNA by intradermal electroporation efficiently boosts DNA-primed T and B cell responses to carcinoembryonic antigen.

Bråve A, Hallengärd D, Gudmundsdotter L, Stout R, Walters R, Wahren B, Hallermalm K.

Vaccine. 2009 Jun 8;27(28):3692-6. doi: 10.1016/j.vaccine.2009.04.013. Epub 2009 May 3.

PMID:
19428161
25.

Combining DNA technologies and different modes of immunization for induction of humoral and cellular anti-HIV-1 immune responses.

Bråve A, Hallengärd D, Malm M, Blazevic V, Rollman E, Stanescu I, Krohn K.

Vaccine. 2009 Jan 7;27(2):184-6. doi: 10.1016/j.vaccine.2008.10.041. Epub 2008 Nov 4.

PMID:
18992294
26.

Intranasal immunization of young mice with a multigene HIV-1 vaccine in combination with the N3 adjuvant induces mucosal and systemic immune responses.

Bråve A, Hallengärd D, Schröder U, Blomberg P, Wahren B, Hinkula J.

Vaccine. 2008 Sep 19;26(40):5075-8. doi: 10.1016/j.vaccine.2008.03.066. Epub 2008 Apr 15.

PMID:
18450334
27.

Challenges of Global Vaccine Development.

Gudmundsdotter L, Hallengärd D.

Expert Rev Vaccines. 2008 Feb;7(1):21-3. doi: 10.1586/14760584.7.1.21.

PMID:
18251690

Supplemental Content

Loading ...
Support Center